Has Vikram Jayanty, MD received payments from drug or device companies?

Yes. Drug and device makers reported $926,300 in general payments to Vikram Jayanty, MD across 727 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vikram Jayanty, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vikram Jayanty, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vikram Jayanty, MD

Gastroenterology · Houston, TXNPI 1336166982

Payments from drug & device makers

$926,300in general payments, 2019–2025

Across 727 payments — averaging $1274.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bristol Myers Squibb$399K
Ironwood Pharmaceuticals, Inc$208K
AbbVie$101K
Eli Lilly$81K
Takeda Pharmaceuticals U.S.A., Inc.$47K
Bausch Health US, LLC$33K
plus $57K from 35 others

$25,865in research payments, 2019–2025

Across 3 payments — averaging $8621.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$26K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bristol Myers Squibb	58	$398,719
Ironwood Pharmaceuticals, Inc	62	$207,818
AbbVie(2 entities)	236	$101,120
Eli Lilly	4	$81,270
Takeda Pharmaceuticals U.S.A., Inc.	71	$46,607
Bausch Health US, LLC	15	$33,453
E.r. Squibb & Sons, L.L.C.	7	$19,826
Shire North American Group Inc	10	$19,467
Pfizer	34	$11,665
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	69	$1,295
Johnson & Johnson(4 entities)	36	$1,241
Fujifilm Healthcare Americas Corporation	3	$674
Gilead	24	$449
Ardelyx, Inc.	15	$327
Madrigal Pharmaceuticals	9	$284
Redhill Biopharma Inc.	14	$258
Phathom Pharmaceuticals, Inc.	6	$244
Medtronic(2 entities)	2	$160
Sanofi	5	$139
Ferring Pharmaceuticals Inc.	7	$139
Abbott	1	$127
Novo Nordisk	2	$116
Lilly USA, LLC	4	$104
Evoke Pharma, Inc.	5	$104
Regeneron Healthcare Solutions, Inc.	3	$101
Actelion Pharmaceuticals US, Inc.	1	$96
Boehringer Ingelheim International GmbH	2	$80
Celltrion USA Inc.	3	$50
QOL Medical, LLC	3	$47
Endo Pharmaceuticals Inc.	3	$46
Boston Scientific	2	$43
Baxter Healthcare	1	$40
Olympus America Inc.	1	$38
Intercept Pharmaceuticals, Inc.	2	$32
Capsovision, Inc.	1	$25
Biocon Biologics Inc	1	$23
Aimmune Therapeutics, Inc.	1	$18
Nestle Healthcare Nutrition Inc.	1	$17
AstraZeneca	1	$14
Braintree Laboratories, Inc.	1	$14
Endogastric Solutions, Inc	1	$9

How this compares

$926,300 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas →

Medicare billing

Part B allowed, 2024

$185,456

Medicare patients

233

Services billed

1,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Houston

Mazen NoureddinHouston$6.1M
James MaherHouston$5.3M
Uma MohanHouston$5M
John VierlingHouston$2.8M
Bincy AbrahamHouston$2.5M
Jason HouHouston$2.3M
Jignesh ShahHouston$1.7M
Mouhamad Al-SabbaghHouston$1.6M
Mohamed OthmanHouston$1.6M
Harry OjeasHouston$1.5M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →